Delivery of Protein Kinase A by CRISPRMAX and Its Effects on Breast Cancer Stem-Like Properties.
CRISPRMAX
cancer stem cells
chemoresistance
drug delivery
epithelial-mesenchymal transition
protein kinase A
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
23 Dec 2020
23 Dec 2020
Historique:
received:
06
11
2020
revised:
14
12
2020
accepted:
18
12
2020
entrez:
30
12
2020
pubmed:
31
12
2020
medline:
31
12
2020
Statut:
epublish
Résumé
Protein kinase A (PKA) activation has recently been reported to inhibit epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) ability, which is considered to be responsible for chemoresistance and tumor recurrence in patients. While current studies mainly focus on gene manipulation of the EMT process, the direct delivery of PKA enzymes to cancer cells has never been investigated. Here, we utilize the commercial Lipofectamine CRISPRMAX reagent to directly deliver PKAs to breast cancer cells and evaluate its effects on EMT regulation. We optimized the delivery parameters with fluorescent-labeled bovine serum albumin, and successfully delivered fluorescent PKAs through CRISPRMAX into breast cancer cells. Then, we evaluated the biological effects by immunofluorescence, flow cytometry, mammosphere assay, and chemoresistance assay. Our data showed the expression of EMT-related markers, α-smooth muscle actin and N-cadherin, was downregulated after CRISPRMAX-PKA treatment. Although the CD44
Identifiants
pubmed: 33374889
pii: pharmaceutics13010011
doi: 10.3390/pharmaceutics13010011
pmc: PMC7824330
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Distinguished Clinical Investigator Grant of Jiangsu Province, China
ID : JSTP201701
Organisme : Jiangsu Provincial Key Research and Development Programme
ID : BE2018690
Organisme : Academy of Finland
ID : 328933
Organisme : Sigrid Juséliuksen Säätiö
ID : 28002247K1
Organisme : China Scholarships Council
ID : No. 201803170073, No.201909110009
Références
Adv Mater. 2016 Dec;28(46):10195-10203
pubmed: 27689681
J Control Release. 2012 Nov 10;163(3):322-34
pubmed: 22989535
Curr Opin Biotechnol. 2003 Aug;14(4):444-50
pubmed: 12943856
Anal Bioanal Chem. 2017 Sep;409(24):5779-5787
pubmed: 28762066
Nanomaterials (Basel). 2019 Apr 02;9(4):
pubmed: 30986952
J Biol Chem. 2016 Jun 17;291(25):12917-29
pubmed: 27129262
Nat Commun. 2015 Jun 04;6:7240
pubmed: 26041070
J Cell Biol. 2008 Aug 25;182(4):623-9
pubmed: 18710927
Biotechnol Lett. 2016 Jun;38(6):919-29
pubmed: 26892225
J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):175-81
pubmed: 11990302
Cancer Res. 2002 Oct 1;62(19):5443-50
pubmed: 12359751
Leukemia. 2020 May 12;:
pubmed: 32398790
Nat Rev Cancer. 2009 Apr;9(4):265-73
pubmed: 19262571
Adv Healthc Mater. 2017 Sep;6(18):
pubmed: 28738444
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Mol Cell Oncol. 2020 Mar 26;7(3):1735911
pubmed: 32391428
J Liposome Res. 2008;18(3):235-48
pubmed: 18770073
Bioeng Transl Med. 2016 Jun 03;1(1):10-29
pubmed: 29313004
Front Pharmacol. 2015 Dec 01;6:286
pubmed: 26648870
J Pharm Pharmacol. 2013 Feb;65(2):157-70
pubmed: 23278683
Cancer Biol Med. 2017 Aug;14(3):228-241
pubmed: 28884040
J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):111-7
pubmed: 22665270
Pharmaceutics. 2018 May 18;10(2):
pubmed: 29783687
FEBS Open Bio. 2020 Sep;10(9):1737-1747
pubmed: 32662250
Stem Cells Transl Med. 2019 Jan;8(1):75-81
pubmed: 30328686
FEBS J. 2019 Dec;286(24):4889-4909
pubmed: 31715067
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Methods Enzymol. 2012;505:3-21
pubmed: 22289445
Eur J Pharm Sci. 2020 Mar 1;144:105213
pubmed: 31926941
J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):235-52
pubmed: 20521089
Mol Oncol. 2017 Jul;11(7):878-891
pubmed: 28544151
Nano Today. 2019 Apr;25:85-98
pubmed: 31360214
Anal Chem. 2020 Aug 18;92(16):11453-11461
pubmed: 32664723
Biochem Biophys Res Commun. 2014 Oct 10;453(1):112-6
pubmed: 25261721
Biochem J. 2004 Jan 1;377(Pt 1):159-69
pubmed: 14505488
Blood. 2002 Mar 15;99(6):1986-94
pubmed: 11877270
Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7744-7749
pubmed: 30926671
Adv Mater. 2018 Jun;30(24):e1703658
pubmed: 29389041
Nature. 2015 Nov 26;527(7579):472-6
pubmed: 26560033
Oncogene. 2004 Mar 15;23(11):2016-27
pubmed: 15021889
Hepatology. 2015 Sep;62(3):801-15
pubmed: 25953743
Breast Cancer Res Treat. 2012 Feb;132(1):153-64
pubmed: 21584665
Nat Commun. 2020 Aug 13;11(1):4043
pubmed: 32792475
Genomics. 2020 Sep;112(5):3306-3314
pubmed: 32544548
Hepatology. 2018 Jun;67(6):2226-2243
pubmed: 29171033
Nat Commun. 2019 Nov 14;10(1):5165
pubmed: 31727883
Curr Med Chem. 2019;26(13):2285-2296
pubmed: 30963961
Bioact Mater. 2020 Mar 18;5(2):358-363
pubmed: 32206737
Science. 2016 Mar 4;351(6277):aad3680
pubmed: 26941323
Bioact Mater. 2017 Jul 17;2(4):269-280
pubmed: 29744436